The key components of cardiovascular risk reduction include inflammation reduction and improving metabolic health. Key biomarkers are analyzed to stratify risk and assess for lipoprotein status as well as arterial wall inflammation (eg Lp(a)-P, hs CRP, Lp-PLA2, homocysteine and myeloperoxidase).
Treatment and risk reduction is centered around lifestyle changes to incorporate inflammation reducing eating plans, stress reduction, and resolution of root causes of inflammation. This may include evaluation of gut health, toxin exposure and hormone analysis.
- Sleep Apnea
- Metabolic Syndrome
- Heart Disease